Phosphatase of regenerating liver: A novel target for cancer therapy

Amanda M. Campbell, Zhong-Yin Zhang

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Introduction: Phosphatases of regenerating livers (PRLs) are novel oncogenes that interact with many well-established cell signaling pathways that are misregulated in cancer, and are known to drive cancer metastasis when overexpressed. Areas covered: This review covers basic information of the discovery and characteristics of the PRL family. We also report findings on the role of PRL in cancer, cell functions and cell signaling. Furthermore, PRL's suitability as a novel drug target is discussed along with current methods being developed to facilitate PRL inhibition. Expert opinion: PRLs show great potential as novel drug targets for anticancer therapeutics. Studies indicate that PRL can perturb major cancer pathways such as Src/ERK1/2 and PTEN/PI3K/Akt. Upregulation of PRLs has also been shown to drive cancer metastasis. However, in order to fully realize its therapeutic potential, a deeper understanding of the function of PRL in normal tissue and in cancer must be obtained. Novel and integrated biochemical, chemical, biological, and genetic approaches will be needed to identify PRL substrate(s) and to provide proof-of-concept data on the druggability of the PRL phosphatases.

Original languageEnglish
Pages (from-to)555-569
Number of pages15
JournalExpert Opinion on Therapeutic Targets
Volume18
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Phosphoric Monoester Hydrolases
Liver
Neoplasms
Therapeutics
Cell signaling
Neoplasm Metastasis
Expert Testimony
Liver Neoplasms
Phosphatidylinositol 3-Kinases
Oncogenes
Pharmaceutical Preparations
Up-Regulation
Tissue

Keywords

  • Adhesion junctions
  • Adhesion molecules
  • Cell migration
  • Colorectal cancer
  • De-trimerization
  • Epithelial to mesenchymal transition
  • Extracellular signal regulated kinases 1 and 2
  • Filamentous actin dynamics
  • Monoclonal antibody targeting
  • Phosphatase and tensin homologue deleted on chromosome 10
  • Phosphatase of regenerating liver
  • PI3K/Akt
  • Receptor tyrosine kinases
  • Small molecule inhibition
  • Src kinase

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine
  • Medicine(all)

Cite this

Phosphatase of regenerating liver : A novel target for cancer therapy. / Campbell, Amanda M.; Zhang, Zhong-Yin.

In: Expert Opinion on Therapeutic Targets, Vol. 18, No. 5, 2014, p. 555-569.

Research output: Contribution to journalArticle

@article{5012352b63774bc6a1b22e52c1448b81,
title = "Phosphatase of regenerating liver: A novel target for cancer therapy",
abstract = "Introduction: Phosphatases of regenerating livers (PRLs) are novel oncogenes that interact with many well-established cell signaling pathways that are misregulated in cancer, and are known to drive cancer metastasis when overexpressed. Areas covered: This review covers basic information of the discovery and characteristics of the PRL family. We also report findings on the role of PRL in cancer, cell functions and cell signaling. Furthermore, PRL's suitability as a novel drug target is discussed along with current methods being developed to facilitate PRL inhibition. Expert opinion: PRLs show great potential as novel drug targets for anticancer therapeutics. Studies indicate that PRL can perturb major cancer pathways such as Src/ERK1/2 and PTEN/PI3K/Akt. Upregulation of PRLs has also been shown to drive cancer metastasis. However, in order to fully realize its therapeutic potential, a deeper understanding of the function of PRL in normal tissue and in cancer must be obtained. Novel and integrated biochemical, chemical, biological, and genetic approaches will be needed to identify PRL substrate(s) and to provide proof-of-concept data on the druggability of the PRL phosphatases.",
keywords = "Adhesion junctions, Adhesion molecules, Cell migration, Colorectal cancer, De-trimerization, Epithelial to mesenchymal transition, Extracellular signal regulated kinases 1 and 2, Filamentous actin dynamics, Monoclonal antibody targeting, Phosphatase and tensin homologue deleted on chromosome 10, Phosphatase of regenerating liver, PI3K/Akt, Receptor tyrosine kinases, Small molecule inhibition, Src kinase",
author = "Campbell, {Amanda M.} and Zhong-Yin Zhang",
year = "2014",
doi = "10.1517/14728222.2014.892926",
language = "English",
volume = "18",
pages = "555--569",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Phosphatase of regenerating liver

T2 - A novel target for cancer therapy

AU - Campbell, Amanda M.

AU - Zhang, Zhong-Yin

PY - 2014

Y1 - 2014

N2 - Introduction: Phosphatases of regenerating livers (PRLs) are novel oncogenes that interact with many well-established cell signaling pathways that are misregulated in cancer, and are known to drive cancer metastasis when overexpressed. Areas covered: This review covers basic information of the discovery and characteristics of the PRL family. We also report findings on the role of PRL in cancer, cell functions and cell signaling. Furthermore, PRL's suitability as a novel drug target is discussed along with current methods being developed to facilitate PRL inhibition. Expert opinion: PRLs show great potential as novel drug targets for anticancer therapeutics. Studies indicate that PRL can perturb major cancer pathways such as Src/ERK1/2 and PTEN/PI3K/Akt. Upregulation of PRLs has also been shown to drive cancer metastasis. However, in order to fully realize its therapeutic potential, a deeper understanding of the function of PRL in normal tissue and in cancer must be obtained. Novel and integrated biochemical, chemical, biological, and genetic approaches will be needed to identify PRL substrate(s) and to provide proof-of-concept data on the druggability of the PRL phosphatases.

AB - Introduction: Phosphatases of regenerating livers (PRLs) are novel oncogenes that interact with many well-established cell signaling pathways that are misregulated in cancer, and are known to drive cancer metastasis when overexpressed. Areas covered: This review covers basic information of the discovery and characteristics of the PRL family. We also report findings on the role of PRL in cancer, cell functions and cell signaling. Furthermore, PRL's suitability as a novel drug target is discussed along with current methods being developed to facilitate PRL inhibition. Expert opinion: PRLs show great potential as novel drug targets for anticancer therapeutics. Studies indicate that PRL can perturb major cancer pathways such as Src/ERK1/2 and PTEN/PI3K/Akt. Upregulation of PRLs has also been shown to drive cancer metastasis. However, in order to fully realize its therapeutic potential, a deeper understanding of the function of PRL in normal tissue and in cancer must be obtained. Novel and integrated biochemical, chemical, biological, and genetic approaches will be needed to identify PRL substrate(s) and to provide proof-of-concept data on the druggability of the PRL phosphatases.

KW - Adhesion junctions

KW - Adhesion molecules

KW - Cell migration

KW - Colorectal cancer

KW - De-trimerization

KW - Epithelial to mesenchymal transition

KW - Extracellular signal regulated kinases 1 and 2

KW - Filamentous actin dynamics

KW - Monoclonal antibody targeting

KW - Phosphatase and tensin homologue deleted on chromosome 10

KW - Phosphatase of regenerating liver

KW - PI3K/Akt

KW - Receptor tyrosine kinases

KW - Small molecule inhibition

KW - Src kinase

UR - http://www.scopus.com/inward/record.url?scp=84905039727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905039727&partnerID=8YFLogxK

U2 - 10.1517/14728222.2014.892926

DO - 10.1517/14728222.2014.892926

M3 - Article

C2 - 24579927

AN - SCOPUS:84905039727

VL - 18

SP - 555

EP - 569

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 5

ER -